Literature DB >> 32096475

Effect of folate supplementation on immunological and autophagy markers in experimental nonalcoholic fatty liver disease.

Sara Youssry1, Maher A Kamel2.   

Abstract

BACKGROUND AND AIMS: Chronic hepatic inflammation is an important pathogenic mediator of nonalcoholic fatty liver disease (NAFLD) that contributes to disease severity. It is commonly suggested that autophagy dysfunction may be an underlying cause of nonalcoholic fatty liver disease. However, the exact role of autophagy in lipid metabolism remains controversial. There has been a growing interest in the role of folate supplementation for the treatment and/or prevention of NAFLD. We aimed in this study to investigate the effects of different doses of folate supplementation on several immune markers and autophagy trying to explore the complex role of IL-22 and autophagy in NAFLD.
METHODS: Fifty Wistar rats were randomly separated into experimental (n = 40) and control groups (n = 10), which were fed for eight weeks with a high-fat diet (HFD) containing 40% fats or a standard diet, respectively. The experimental group was further subdivided into four subgroups where the first subgroup was left untreated while the other three were treated with different doses of folate (50, 100, and 150 μg/kg of body weight, respectively). At the end of the experimental period, animals from each group were sacrificed for blood and tissue analyses.
RESULTS: NAFLD rats showed decreased IL-22 serum levels and increased LC3B expression as compared to controls. Folate treatment was significantly associated with improvement in disease parameters, reduced presence of the pro-inflammatory cytokines TNF-α and CXCL8 and LC3B expression, and increased IL-22 levels in a dose-dependent manner.
CONCLUSION: These results highlight the capacity of folate to modulate the production of several pro-inflammatory cytokines and autophagy thereby having a favorable impact disease progression.

Entities:  

Keywords:  CXCL8; Folate; IL-22; LC3B; Nonalcoholic Fatty Liver Disease; TNF-α

Mesh:

Substances:

Year:  2019        PMID: 32096475     DOI: 10.1684/ecn.2019.0437

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  2 in total

1.  Galangin Improved Non-Alcoholic Fatty Liver Disease in Mice by Promoting Autophagy.

Authors:  Xinxu Zhang; Yuanyuan Deng; Juan Xiang; Huixia Liu; Jiani Zhang; Jie Liao; Ke Chen; Bo Liu; Jun Liu; Ying Pu
Journal:  Drug Des Devel Ther       Date:  2020-08-19       Impact factor: 4.162

2.  Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2.

Authors:  Xiaomeng Chen; Hong Ma; Yan Gao; Ye Jin; Wei Ning; Yue Hou; Jianrong Su
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.